Afferent Pharmaceuticals announces preclinical in vivo results of P2X3 receptor
Links shared publicly online about this topic.
- 920total visits
Afferent Pharmaceuticals announces preclinical in vivo results of P2X3 receptor
Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecule compounds that target P2X3 receptors, today announced preclinical in vivo results demonstrating that an investigational P2X3 receptor antagonist reduced experimentally induced bladder hyperactivity.
View full resource at news-medical.net
Tags: Urinary System, Pharma
Most Recently Shared on August 26, 2010 at 5:41 am By:
Afferent Pharmaceuticals announces preclinical in vivo results of P2X3 receptor: Afferent Pharmaceuticals, a clini... http://bit.ly/d30hhs
Afferent Pharmaceuticals Presents Data Supporting Use Of P2X3 Antagonists In Reducing Bone Cancer Pain
medicalnewstoday.com — “Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecules that target P2X3 receptors, announced preclinical in vivo results demonstrating that” View full resource at medicalnewstoday.com
Most Recently Shared on September 3, 2010 at 3:00 pm By:
MNT Bones/Orthopedic Health News
Afferent Pharmaceuticals Presents Data Supporting Use Of P2X3 Antagonists In Reducing Bone Cancer Pain http://mnt.to/3Jft
Advertisement
